According to This site(Wegovy and Mounjaro World Information), you can easily get one.
Based on the search results, here is the global data for the purchase of Wegovy and Mounjaro:
-
Novo Nordisk's Wegovy:
- Sales of Wegovy have been rapidly growing, with a significant increase in the first six months of 2024. In the U.S. alone, sales of Wegovy soared 344% to nearly $1.7 billion.
- Novo Nordisk expects sales of Wegovy and its other weight-loss injectable, Saxenda, to reach $6.1 billion before the year is out and $15 billion annually by 2030.
- The company anticipates filing for regulatory approvals of a label indication expansion for Wegovy in the U.S. and the European Union this year, highlighting the drug's cardiovascular benefits.
-
Eli Lilly's Mounjaro:
- Mounjaro, also known as tirzepatide, is a drug developed by Eli Lilly. It received FDA approval for obesity in November 2023.
- GlobalData, a data and analytics company, forecasts that Mounjaro will surpass Novo Nordisk's Ozempic and become the leading drug by sales in the obesity and diabetes market. It is projected to achieve sales of $27 billion in 2029.
- Mounjaro's superior efficacy over Ozempic has been demonstrated in a meta-analysis of 22 trials.
Weight loss pens Wegovy and Mounjaro are two prescription medications that are used for weight loss and management. While both drugs have similarities in terms of their mechanism of action, there are several important differences between them. This article aims to provide a comprehensive overview of the key differences between Wegovy and Mounjaro.
1. FDA-Approved Uses:
- Wegovy: Wegovy (semaglutide) is FDA-approved for long-term weight management in adults with a body mass index (BMI) of 30 or higher (obesity).
- Mounjaro: Mounjaro (tirzepatide) is currently FDA-approved for the treatment of type 2 diabetes in adults . However, doctors may sometimes prescribe it off-label for weight loss.
2. Mechanism of Action:
- Wegovy: Wegovy mimics the action of a hormone called glucagon-like peptide-1 (GLP-1), which helps regulate appetite.
- Mounjaro: Mounjaro not only mimics GLP-1 but also another appetite-regulating hormone called glucose-dependent insulinotropic polypeptide (GIP).
3. Approved Use in Children:
- Wegovy: Wegovy is FDA-approved for weight management in certain children aged 12 years and older with a BMI in the 95th percentile or higher (obesity).
- Mounjaro: Mounjaro is not approved for use in children under the age of 18 years.
4. Dosage and Administration:
- Wegovy: The recommended dosage of Wegovy is given in milligrams per milliliter (mg/mL) of solution, and it is administered through injection into the upper arm, abdomen, or thigh.
- Mounjaro: Similar to Wegovy, Mounjaro is also administered through injection into the upper arm, abdomen, or thigh, with recommended doses given in mg/mL of solution.
5. Comparative Effectiveness:
- Clinical Trials: While Wegovy and Mounjaro have not been directly compared in clinical trials for weight loss, a review of trials found that Mounjaro, taken at the maximum dose of 15 mg once per week, was associated with greater weight loss than Wegovy, taken at the maximum dose of 2.4 mg once per week.
- Treatment Guidelines: Wegovy is recommended as a treatment option for people with obesity in guidelines from the American Gastroenterological Association, while Mounjaro is recommended for people with type 2 diabetes who could benefit from weight management medication, according to the American Diabetes Association.
Conclusion:
In summary, while both Wegovy and Mounjaro are weight loss pens, they have distinct differences in their FDA-approved uses, mechanism of action, approved use in children, dosage and administration, and comparative effectiveness. It is important to consult with a healthcare professional to determine which medication may be most suitable for individual weight loss goals and medical conditions.